MX2016014429A - Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos. - Google Patents
Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos.Info
- Publication number
- MX2016014429A MX2016014429A MX2016014429A MX2016014429A MX2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- movement disorders
- hyperkinetic movement
- vmat2 inhibitors
- vmat2
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000000269 Hyperkinesis Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000001660 hyperkinetic effect Effects 0.000 abstract 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen métodos para tratar enfermedades y trastornos hipercinéticos, tal como discinesia tardía. En una cierta modalidad, el inhibidor VMAT2 potente (+)a-3-isobutil-9,10-dimetox i-1,3,4,6,7,11b-hexahidro-2H-pirido [2,1-a] isoquinolin-2-ol ((+)a-HTBZ) se usa en los métodos descritos en la presente para tratar a un sujeto en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989240P | 2014-05-06 | 2014-05-06 | |
| PCT/US2015/029519 WO2015171802A1 (en) | 2014-05-06 | 2015-05-06 | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014429A true MX2016014429A (es) | 2017-04-06 |
| MX387625B MX387625B (es) | 2025-03-18 |
Family
ID=53264772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014429A MX387625B (es) | 2014-05-06 | 2015-05-06 | Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20170071932A1 (es) |
| EP (3) | EP3139925B1 (es) |
| JP (4) | JP6635945B2 (es) |
| KR (5) | KR20250029267A (es) |
| CN (3) | CN112741836A (es) |
| AU (1) | AU2015256012B2 (es) |
| CA (1) | CA2947736C (es) |
| CY (1) | CY1125058T1 (es) |
| DK (2) | DK3936130T3 (es) |
| ES (2) | ES2976207T3 (es) |
| FI (1) | FI3936130T3 (es) |
| HR (2) | HRP20220025T1 (es) |
| HU (2) | HUE057839T2 (es) |
| IL (1) | IL248745B (es) |
| LT (2) | LT3936130T (es) |
| MX (1) | MX387625B (es) |
| NZ (1) | NZ725826A (es) |
| PL (2) | PL3139925T3 (es) |
| PT (2) | PT3139925T (es) |
| RS (2) | RS65359B1 (es) |
| RU (1) | RU2753740C2 (es) |
| SI (2) | SI3936130T1 (es) |
| SM (2) | SMT202400199T1 (es) |
| WO (1) | WO2015171802A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10065952B2 (en) * | 2015-10-30 | 2018-09-04 | Neurocrine Biosciences, Inc. | Valbenazine salts and polymorphs thereof |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| ES2811048T3 (es) * | 2016-06-29 | 2021-03-10 | Crystal Pharmaceutical Suzhou Co Ltd | Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas |
| TW202345829A (zh) * | 2016-12-02 | 2023-12-01 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| KR20190108146A (ko) | 2017-01-27 | 2019-09-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2020508337A (ja) | 2017-02-27 | 2020-03-19 | サンド・アクチエンゲゼルシヤフト | バルベナジン塩の結晶形態 |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| CA3057543A1 (en) * | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
| GB201705305D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| AU2018241940B2 (en) * | 2017-04-01 | 2023-09-28 | Adeptio Pharmaceuticals Limited | Dihydrotetrabenazine for use in the treatment a movement disorder |
| US20190111035A1 (en) * | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| WO2018200605A1 (en) * | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| CN111372567B (zh) | 2017-09-21 | 2024-03-15 | 纽罗克里生物科学有限公司 | 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| EP3706748A4 (en) * | 2017-11-08 | 2021-08-11 | Foresee Pharmaceuticals Co., Ltd. | ESTER OF DIHYDROTETRABENAZINE |
| JP7212958B2 (ja) | 2017-12-26 | 2023-01-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | バルベナジントシル酸塩の結晶形及びその製造方法並びに用途 |
| DK3784237T3 (da) * | 2018-04-25 | 2024-01-08 | Shinkei Therapeutics Inc | Indretning til transdermal levering af tetrabenazin |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| CA3100694A1 (en) | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| IL321020A (en) * | 2019-05-09 | 2025-07-01 | Neurocrine Biosciences Inc | Methods of administering certain vmat2 inhibitors |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2081929T3 (da) * | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| US7871706B2 (en) * | 2006-11-09 | 2011-01-18 | New York University | Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| ES2652289T3 (es) | 2008-09-18 | 2018-02-01 | Auspex Pharmaceuticals, Inc. | Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2 |
| EP2464340A2 (en) * | 2009-08-12 | 2012-06-20 | Valeant International (Barbados) SRL | Pharmaceutical compositions with tetrabenazine |
| CN104744456A (zh) * | 2010-06-01 | 2015-07-01 | 奥斯拜客斯制药有限公司 | Vmat2的苯并喹啉酮抑制剂 |
| CN116768882A (zh) * | 2012-09-18 | 2023-09-19 | 奥斯拜客斯制药有限公司 | 化合物、及其药物组合物及治疗方法 |
| RU2757221C2 (ru) * | 2014-02-07 | 2021-10-12 | Ньюрокрайн Байосайенсиз, Инк. | Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение |
-
2015
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
-
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
-
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
-
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
-
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014429A (es) | Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos. | |
| FR21C1048I2 (fr) | Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| MX374633B (es) | Combinaciones terapeuticas para usarse en el tratamiento de tumores. | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| ES2764110T8 (es) | Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer | |
| ES2727103T8 (es) | Conjugado anticuerpo-fármaco para IGF-1R y su utilización para el tratamiento del cáncer | |
| CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX2016013950A (es) | Metodo para producir l-aminoacidos utilizando una bacteria alcalifilica. | |
| DK3229840T5 (da) | 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| UY36286A (es) | Tratamientos médicos basados en anamorelina | |
| CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos | |
| UY36070A (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos | |
| MX2017007338A (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis. |